AI Engines For more Details: Perplexity Kagi Labs You
Seizure Control: Oxcarbazepine is approved for the treatment of partial seizures in adults and children aged 4 years and older. It works by stabilizing electrical activity in the brain, which helps to prevent seizures from occurring.
Epilepsy Management: It is effective in reducing the frequency and severity of seizures in individuals with epilepsy. It may be used alone or in combination with other antiepileptic medications to achieve optimal seizure control.
Mood Stabilization: In addition to its anticonvulsant properties, oxcarbazepine has mood-stabilizing effects. It is sometimes prescribed off-label for the treatment of bipolar disorder to help stabilize mood swings and prevent manic episodes.
Off-Label Uses: While oxcarbazepine is primarily indicated for epilepsy and bipolar disorder, it may also be prescribed off-label for other conditions such as neuropathic pain, trigeminal neuralgia, and impulse control disorders.
Tolerability: Oxcarbazepine is generally well-tolerated, with fewer drug interactions compared to older anticonvulsant medications like carbamazepine. It has a lower risk of causing adverse effects on liver function and blood cell counts.
Side Effects: Common side effects of oxcarbazepine may include dizziness, drowsiness, headache, nausea, vomiting, fatigue, and double vision. These side effects are usually mild and transient, but they may require dose adjustments or discontinuation of the medication in some cases.
Serious Side Effects: Although rare, oxcarbazepine can cause more serious side effects such as allergic reactions, including rash, fever, swollen glands, and liver problems. It may also increase the risk of suicidal thoughts or behaviors, especially in individuals with a history of depression or mood disorders.
Drug Interactions: Oxcarbazepine may interact with certain medications, including other antiepileptic drugs, oral contraceptives, and antidepressants. It is important for healthcare providers to review all medications a patient is taking to avoid potential interactions.
Pregnancy and Breastfeeding: Oxcarbazepine may pose risks to pregnant women and their developing fetuses. Women of childbearing age should use effective contraception while taking oxcarbazepine, and pregnant women should discuss the risks and benefits of the medication with their healthcare provider.
Monitoring: Regular monitoring of liver function tests and blood cell counts may be recommended during long-term treatment with oxcarbazepine to detect any potential adverse effects.
Discontinuation: Abrupt discontinuation of oxcarbazepine should be avoided, as it may lead to increased seizure activity or withdrawal symptoms. Dosage should be gradually tapered under medical supervision when discontinuing treatment.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
| Acne | 0.6 | 0.6 | 0 |
| ADHD | 5.1 | 0.9 | 4.67 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 2.8 | 0 |
| Allergies | 7.8 | 4.9 | 0.59 |
| Allergy to milk products | 2.2 | 1.6 | 0.38 |
| Alopecia (Hair Loss) | 1.4 | 1.4 | |
| Alzheimer's disease | 7.3 | 6.4 | 0.14 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.1 | 1.1 | 2.73 |
| Ankylosing spondylitis | 4 | 1.2 | 2.33 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 1.1 | 1.1 | |
| Asthma | 5.7 | 3.2 | 0.78 |
| Atherosclerosis | 2.3 | 2.4 | -0.04 |
| Atrial fibrillation | 4.1 | 2 | 1.05 |
| Autism | 10.8 | 9.9 | 0.09 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.6 | 1.6 | |
| Bipolar Disorder | 2.1 | 1.7 | 0.24 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1 | 0.3 | 2.33 |
| Cancer (General) | 0.9 | 2.5 | -1.78 |
| Carcinoma | 4.6 | 2.6 | 0.77 |
| Celiac Disease | 2.6 | 3.7 | -0.42 |
| Cerebral Palsy | 1.7 | 1.3 | 0.31 |
| Chronic Fatigue Syndrome | 5.3 | 6.3 | -0.19 |
| Chronic Kidney Disease | 4.1 | 2.4 | 0.71 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.2 | 2 | 0.1 |
| Chronic Urticaria (Hives) | 1.6 | 1.3 | 0.23 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1.3 | 0.15 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 9.7 | 3 | 2.23 |
| Constipation | 2.1 | 1.3 | 0.62 |
| Coronary artery disease | 2 | 2.7 | -0.35 |
| COVID-19 | 11.2 | 12.1 | -0.08 |
| Crohn's Disease | 8.2 | 6.4 | 0.28 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.8 | 1.9 | -1.37 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 3.2 | 1.4 | 1.29 |
| Denture Wearers Oral Shifts | 1.4 | 1.4 | |
| Depression | 12 | 9.5 | 0.26 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 2.8 | -0.65 |
| Endometriosis | 3.1 | 2.2 | 0.41 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.8 | 2.4 | 0.58 |
| erectile dysfunction | 2 | 0.3 | 5.67 |
| Fibromyalgia | 3.4 | 1.8 | 0.89 |
| Functional constipation / chronic idiopathic constipation | 5.8 | 3.9 | 0.49 |
| gallstone disease (gsd) | 3.4 | 1.4 | 1.43 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2 | 1.2 | 0.67 |
| Generalized anxiety disorder | 2.7 | 2.7 | 0 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.1 | 1.4 | 0.5 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2.4 | -1.67 |
| Halitosis | 1.4 | 0.3 | 3.67 |
| Hashimoto's thyroiditis | 4 | 1.5 | 1.67 |
| Heart Failure | 4 | 1.9 | 1.11 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.5 | 0.6 | 1.5 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.6 | 0.17 |
| hyperglycemia | 2.2 | 2.1 | 0.05 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 5.1 | 6.3 | -0.24 |
| Hypothyroidism | 0.3 | 1 | -2.33 |
| Hypoxia | 3.4 | 0.3 | 10.33 |
| IgA nephropathy (IgAN) | 1.9 | 4.1 | -1.16 |
| Inflammatory Bowel Disease | 9.6 | 9.1 | 0.05 |
| Insomnia | 2.4 | 3.3 | -0.38 |
| Intelligence | 1.4 | 0.1 | 13 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 8.1 | 6 | 0.35 |
| ischemic stroke | 3.1 | 1.7 | 0.82 |
| Liver Cirrhosis | 7.9 | 5.1 | 0.55 |
| Long COVID | 7.7 | 8.6 | -0.12 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.1 | 1.6 | -0.45 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.1 | 0.9 | 0.22 |
| ME/CFS with IBS | 1.1 | 2.3 | -1.09 |
| ME/CFS without IBS | 1.4 | 2.1 | -0.5 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2 | 0.8 | 1.5 |
| Metabolic Syndrome | 7.3 | 8.9 | -0.22 |
| Mood Disorders | 12.2 | 8 | 0.52 |
| multiple chemical sensitivity [MCS] | 1.1 | 0.1 | 10 |
| Multiple Sclerosis | 8 | 5.8 | 0.38 |
| Multiple system atrophy (MSA) | 2.1 | 0.7 | 2 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.5 | -10.67 |
| Neuropathy (all types) | 1 | 2.9 | -1.9 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.5 | 5.4 | 0.02 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 10.9 | 8.5 | 0.28 |
| obsessive-compulsive disorder | 6.2 | 3.5 | 0.77 |
| Osteoarthritis | 2.5 | 1.5 | 0.67 |
| Osteoporosis | 3.1 | 2.2 | 0.41 |
| pancreatic cancer | 2 | 0.6 | 2.33 |
| Parkinson's Disease | 8.9 | 6.8 | 0.31 |
| Polycystic ovary syndrome | 6.6 | 3.1 | 1.13 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.5 | -0.25 |
| Primary sclerosing cholangitis | 3 | 2.4 | 0.25 |
| Psoriasis | 3.8 | 2.9 | 0.31 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.5 | 4.4 | 0.7 |
| Rosacea | 0.9 | 1 | -0.11 |
| Schizophrenia | 7.8 | 3.4 | 1.29 |
| scoliosis | 0.5 | 0.9 | -0.8 |
| Sjögren syndrome | 2.7 | 3 | -0.11 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.9 | 0.5 | 2.8 |
| Stress / posttraumatic stress disorder | 3.1 | 3.4 | -0.1 |
| Systemic Lupus Erythematosus | 4 | 2.4 | 0.67 |
| Tic Disorder | 1.5 | 1.2 | 0.25 |
| Tourette syndrome | 1.2 | 0.3 | 3 |
| Type 1 Diabetes | 5.7 | 4.3 | 0.33 |
| Type 2 Diabetes | 8.9 | 8.8 | 0.01 |
| Ulcerative colitis | 6.8 | 7.5 | -0.1 |
| Unhealthy Ageing | 5.3 | 2.5 | 1.12 |
| Vitiligo | 2.5 | 1.7 | 0.47 |
